Abstract
Delayed initiation of front-line imatinib therapy predicts for poor response to nilotinib as second-line treatment of imatinib-resistant or intolerant CML: single center report of the ENACT trial in Lebanon
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have